<DOC>
	<DOCNO>NCT02169427</DOCNO>
	<brief_summary>The purpose study determine rate route excretion OPC mass balance urine , faeces expire air .</brief_summary>
	<brief_title>An Open-label Study Healthy Male Subjects Assess Absorption , Distribution , Metabolism Excretion 14C-Labelled BIA 9-1067 Metabolites</brief_title>
	<detailed_description>This single-centre , open-label ADME study 6 healthy male subject . Subjects receive single dose 100 mg OPC , contain 3.39 MBq [ 14C ] OPC oral capsule . The study consist eligibility screening period within 3 week prior drug administration , admission Day -1 , treatment period involve drug administration Day 1 follow matrix collection PK purpose safety evaluation Day 11 , discharge Day 11 , six 24-hour hospitalization Days 14/15 , 21/22 ( +/ 1 day ) , 28/29 ( +/- 1 day ) , 42/43 ( +/- 2 day ) , 56/57 ( +/- 2 day ) 77/78 ( +/ 3 day ) PK sample collection , follow visit perform least 14 day discharge last 24-hour hospitalization early discontinuation .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Opicapone</mesh_term>
	<criteria>1 . Gender : male 2 . Age : 18 55 year , inclusive 3 . Body Mass Index ( BMI ) : 18.0 30.0 kg/m2 , inclusive Body weight ( kg ) height2 ( m2 ) 4 . Ability willingness abstain alcohol , methylxanthinecontaining beverage food ( coffee , tea , cola , chocolate , `` powerdrinks '' ) grapefruit ( juice ) 48 hour prior entry clinical research centre discharge 5 . Medical history without major pathology 6 . Resting supine blood pressure rest pulse rate show clinically relevant deviation judge MI 7 . Computerised ( 12lead ) electrocardiogram ( ECG ) record without sign clinically relevant pathology show clinically relevant deviation judge MI 8 . Willingness use adequate contraception time dose 3 month followup visit 9 . All value haematology clinical chemistry test blood urine within normal range show clinically relevant deviation judge MI 10 . Willingness sign write ICF 1 . Evidence clinically relevant pathology 2 . Mental handicap 3 . History relevant drug and/or food allergy 4 . Regular/routine treatment nontopical medication within 30 day prior entrance clinical research centre 5 . Smoking ( le 60 day prior drug administration ) 6 . History alcohol abuse drug addiction ( include soft drug like cannabis product ) 7 . Use concomitant medication , except acetaminophen ( paracetamol ) , allow 3 day entrance clinical research centre . Multivitamins vitamin C allow 7 day entrance clinical research centre . All medication ( include counter medication , health supplement , herbal remedy St. John 's wort extract ) stop least 14 day prior entrance clinical research centre 8 . Participation drug study within 60 day prior drug administration . Participation 3 drug study 10 month precede administration study drug 9 . Donation 50 mL blood within 60 day prior drug administration . Donation 1.5 litre blood 10 month precede administration study drug 10 . Participation another ADME study radiation burden 0.1 mSv period 1 year start study 11 . Exposure radiation diagnostic reason ( except dental Xrays plain X ray thorax bony skeleton exclude spinal column ) , work participation medical study previous year 12 . Irregular defecation pattern ( less per 2 day ) 13 . Positive screen drug abuse ( opiate , methadone , cocaine , amphetamine , cannabinoids , barbiturate , benzodiazepine , tricyclic antidepressant alcohol ) 14 . Intake 24 unit alcohol per week ( 1 unit alcohol equal approximately 250 mL beer , 100 mL wine 35 mL spirit ) 15 . Positive screen hepatitis B surface antigen ( HBsAg ) 16 . Positive screen antihepatitis C virus ( HCV ) 17 . Positive screen anti human immunodeficiency virus ( HIV ) 1/2 18 . Illness within 5 day prior drug administration</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Parkinson 's disease ( PD )</keyword>
	<keyword>BIA 9-1067</keyword>
	<keyword>Opicapone</keyword>
</DOC>